ArticleFrontiers in pediatrics2025
Case Report: Cystic fibrosis transmembrane conductance regulator gene heterozygous variation presenting with abdominal pain and hepatopancreatic lesions in a child.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accidental arterial PICC placement in neonatal patients: a case series.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to multi-system involvement. Case report: A 4-year-old girl presented with a 2-day history of abdominal pain. Clinical manifestations included recurrent epigastric pain and vomiting. Physical examination revealed abdominal distension, mild periumbilical tenderness, and hepatomegaly (liver palpable 4 cm below the right costal margin). Laboratory tests showed elevated pancreatic enzymes: serum amylase 607 U/L, lipase 634 U/L, and pancreatic amylase 252 U/L (all >3 times the upper limit of normal). Abdominal ultrasound demonstrated diffuse hepatic lesions and uneven echogenicity in pancreatic parenchyma. Computed tomography revealed chronic liver disease changes, possible cirrhosis and a slightly enlarged spleen. Hepatobiliary histopathological biopsy indicated biliary obstruction. Whole-exome sequencing identified CFTR allele variants c.3139G > T (paternal source) and c.1409T > A (maternal source). Comparative analysis with the existing literature verified that the G > T mutation at chromosome 7 (chr7):117250723 was previously unreported. Treatment with octreotide, omeprazole, and pancreatic enzyme replacement therapy led to symptom resolution. At follow-up, her condition remained stable: height=109 cm (10th to 25th percentile), weight=18.8 kg (25th to 50th percentile) and stable condition. Conclusion: The clinical manifestations of CF are diverse, and digestive tract symptoms are common; therefore, early identification and diagnosis are required. As chr7: 117250723 G > T may be a pathogenic gene, long-term follow-up is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.